Published in Neuro Oncol on September 24, 2014
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas | NCT01550523
Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 1.01
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A (2015) 0.98
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence. Front Oncol (2015) 0.87
Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells. Transl Lung Cancer Res (2015) 0.85
Liquid biopsies in patients with diffuse glioma. Acta Neuropathol (2015) 0.82
Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System. Front Neurol (2015) 0.80
Glial biomarkers in human central nervous system disease. Glia (2016) 0.77
Tumor-Associated CSF MicroRNAs for the Prediction and Evaluation of CNS Malignancies. Int J Mol Sci (2015) 0.76
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Vascular endothelial growth factor and angiogenesis. Pharmacol Rev (2004) 5.41
Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 4.98
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol (2008) 4.66
The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol (1999) 4.65
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol (2005) 4.57
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun (2005) 4.06
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol (1995) 3.44
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res (2010) 3.13
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer (2008) 2.89
Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol (2014) 2.87
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (2009) 2.67
Microvesicles: messengers and mediators of tumor progression. Cell Cycle (2009) 2.66
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol (2012) 2.62
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology (2004) 2.61
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Metastatic inefficiency. Adv Cancer Res (1990) 2.40
Transmission of glioblastoma multiforme through liver transplantation. Lancet (1998) 2.33
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol (2014) 2.27
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol (2009) 2.21
Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis (2001) 2.18
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol (2012) 2.02
Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A (2011) 2.01
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol (2009) 1.99
Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res (1996) 1.94
Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res (1984) 1.88
Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol (2009) 1.86
Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol (1999) 1.85
Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res (2005) 1.81
What are biomarkers? Curr Opin HIV AIDS (2010) 1.80
Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci U S A (1976) 1.74
Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol (2010) 1.73
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer (1999) 1.71
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol (2003) 1.66
Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol (2008) 1.64
YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians (1999) 1.62
Glioblastoma multiforme of donor origin after renal transplantation: report of a case. Hum Pathol (1993) 1.62
The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev (2006) 1.59
A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem (2011) 1.58
Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res (2010) 1.57
Serum YKL-40 and colorectal cancer. Br J Cancer (1999) 1.57
Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res (2013) 1.54
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
Establishing the proteome of normal human cerebrospinal fluid. PLoS One (2010) 1.53
Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer (1999) 1.52
Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies. Ann Oncol (2012) 1.49
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol (2000) 1.48
Pineal region tumors in children. J Neurosurg (1988) 1.47
Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia. Transpl Int (1996) 1.47
Radioimmunoassay of glioma-associated antigen in cerebrospinal fluid and its usefulness for the diagnosis and monitoring of human glioma. J Neurooncol (1990) 1.47
YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun (2001) 1.46
RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer (2012) 1.43
High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res (2003) 1.42
Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med (2004) 1.42
Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer (2012) 1.41
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
Matrix metalloproteinases in brain injury. J Neurotrauma (1995) 1.41
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids (2013) 1.40
Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res (1997) 1.38
Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics (2010) 1.36
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res (2002) 1.33
Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol (2011) 1.32
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) (2013) 1.31